Medical hypothesis, discovery & innovation in optometry

Systemic complications of intravitreal bevacizumab: a case report and literature review

Medical hypothesis, discovery & innovation in optometry, Vol. 4 No. 2 (2023), 22 June 2023 , Page 63-75
https://doi.org/10.51329/mehdioptometry175

Abstract

Background: Systemic complications of intravitreal bevacizumab (IVB) injections have been previously reported. We aimed to summarize the systemic complications reported in online primary studies. Moreover, we describe a patient experiencing simultaneous renal and cutaneous drug-induced adverse effects, with exacerbation of chronic renal insufficiency and granulomatous skin lesions, after receiving several IVB injections to manage bilateral ischemic branch retinal vein occlusion (BRVO).
Case Presentation: A 69-year-old Hispanic diabetic man with chronic renal insufficiency due to polyclonal gammopathy received several IVB injections to treat bilateral ischemic BRVO. One week after the sixth injection, the patient developed acute-on-chronic renal failure and multiple rounded maculopapular, erythematous, and ulcerated skin lesions. Renal and skin biopsy specimens revealed granulomatous drug-induced responses in both organs, and granulomatous diseases of infectious and oncological sources were ruled out. We performed an electronic search of the PubMed/MEDLINE database with no language or time restrictions using the keywords “intravitreal bevacizumab” or “intravitreal Avastin” combined with “systemic side effects,” “systemic complications,” or “systemic adverse,” or “systemic adverse event.” The search yielded 147 articles published over almost two decades. After screening and assessment, we selected and summarized 40 primary studies that mentioned IVB-related systemic complications.
Conclusions: IVB-induced systemic complications, such as arteriothrombotic events, venous thrombotic events, and hypertension, are rare but potentially serious. Care should be taken when administering multiple doses of intravitreal IVB to patients with pre-existing kidney dysfunction. Bevacizumab-related toxicity must be considered in cases of sudden deterioration of renal function and / or unexpected granulomatous skin lesions in oncologic or chronically polymedicated patients.
Keywords:
  • state of the art reviews
  • case study
  • avastin
  • intravitreal injection
  • chronic renal insufficiency
  • drug side effect
  • drug toxicity

References

Balci S, Sahin O, Ozcaliskan S, Sevik MO, Mangan MS. Immediate changes in blood pressure during intravitreal anti-VEGF agents' applications in exudative age-related macular degeneration patients. Int Ophthalmol. 2020;40(10):2515-2522. doi: 10.1007/s10792-020-01431-3 pmid: 32495059

Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, et al; GEFAL Study Group. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology. 2013;120(11):2300-9. doi: 10.1016/j.ophtha.2013.06.020 pmid: 23916488

Sharma S, Johnson D, Abouammoh M, Hollands S, Brissette A. Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections. Can J Ophthalmol. 2012;47(3):275-9. doi: 10.1016/j.jcjo.2012.03.026 pmid: 22687306

di Lauro R, De Ruggiero P, di Lauro R, di Lauro MT, Romano MR. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248(6):785-91. doi: 10.1007/s00417-010-1303-3 pmid: 20135139

Bressler NM. Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology. 2009;116(10 Suppl):S15-23. doi: 10.1016/j.ophtha.2009.06.048 pmid: 19800535

Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248(7):915-30. doi: 10.1007/s00417-010-1315-z pmid: 20174816

Wong TY, Scott IU. Clinical practice. Retinal-vein occlusion. N Engl J Med. 2010;363(22):2135-44. doi: 10.1056/NEJMcp1003934 pmid: 21105795

Kameda Y, Babazono T, Uchigata Y, Kitano S. Renal function after intravitreal administration of vascular endothelial growth factor inhibitors in patients with diabetes and chronic kidney disease. J Diabetes Investig. 2018;9(4):937-939. doi: 10.1111/jdi.12771 pmid: 29108104

Wang X, Sawada T, Sawada O, Saishin Y, Liu P, Ohji M. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration. Am J Ophthalmol. 2014;158(4):738-744.e1. doi: 10.1016/j.ajo.2014.06.009 pmid: 24973606

Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina. 2012;32(3):434-57. doi: 10.1097/IAE.0B013E31822C290F pmid: 22374154

Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014;98(12):1636-41. doi: 10.1136/bjophthalmol-2014-305252 pmid: 25001321

Ip MS, Scott IU, Brown GC, Brown MM, Ho AC, Huang SS, et al; American Academy of Ophthalmology. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology. 2008;115(10):1837-46. doi: 10.1016/j.ophtha.2008.08.012 pmid: 18929163

Schmucker C, Loke YK, Ehlken C, Agostini HT, Hansen LL, Antes G, et al. Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Br J Ophthalmol. 2011;95(3):308-17. doi: 10.1136/bjo.2009.178574 pmid: 20971791

Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-98. doi: 10.1016/j.ophtha.2012.03.053 pmid: 22555112

Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015 ;122(1):146-52. doi: 10.1016/j.ophtha.2014.07.041 pmid: 25227499

Touzani F, Geers C, Pozdzik A. Intravitreal Injection of Anti-VEGF Antibody Induces Glomerular Endothelial Cells Injury. Case Rep Nephrol. 2019;2019:2919080. doi: 10.1155/2019/2919080 pmid: 31934470

Roth DB, King A, Weiss M, Klein D. Systemic adverse events after bevacizumab. Ophthalmology. 2009;116(6):1226.e1. doi: 10.1016/j.ophtha.2009.02.011 pmid: 19486800

Fam A, Finger PT. Cutaneous Cell-Mediated Delayed Hypersensitivity to Intravitreal Bevacizumab. Middle East Afr J Ophthalmol. 2020;27(3):182-184. doi: 10.4103/meajo.MEAJO_123_20 pmid: 33488016

Amselem L, Diaz-Llopis M, Garcia-Delpech S, Montero J, Palomares P, Cervera E. Papulopustular eruption after intravitreal bevacizumab (Avastin). Acta Ophthalmol. 2009;87(1):110-1. doi: 10.1111/j.1755-3768.2007.01154.x pmid: 18577190

Johari MK, Askari M, Amini A, Yasemi M. Acute systemic complications of intravitreal bevacizumab and triamcinolone injections - a comparative study. Folia Med (Plovdiv). 2022;64(2):240-247. doi: 10.3897/folmed.64.e61424 pmid: 35851775

Weinstein O, Abu Tailakh M, Lifshitz T, Novack V, Levy J. Intravitreal bevacizumab treatment for neovascular age-related macular degeneration and thromboembolic events. Eur J Ophthalmol. 2020;30(1):66-71. doi: 10.1177/1120672118823128 pmid: 30618282

Kunzmann S, Ngyuen T, Stahl A, Walz JM, Nentwich MM, Speer CP, et al. Necrotizing enterocolitis after intravitreal bevacizumab in an infant with Incontinentia Pigmenti - a case report. BMC Pediatr. 2019;19(1):353. doi: 10.1186/s12887-019-1732-z pmid: 31615465

Lekha T, Prasad HN, Sarwate RN, Patel M, Karthikeyan S. Intravitreal Bevacizumab for Choroidal Neovascularization Associated with Angioid Streaks: Long-term Results. Middle East Afr J Ophthalmol. 2017;24(3):136-142. doi: 10.4103/meajo.MEAJO_17_17 pmid: 29279654

Schauwvlieghe AM, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MG, et al. Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study. PLoS One. 2016;11(5):e0153052. doi: 10.1371/journal.pone.0153052 pmid: 27203434

Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, et al; MANTA Research Group. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013;97(3):266-71. doi: 10.1136/bjophthalmol-2012-302391 pmid: 23292928

Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258-67. doi: 10.1016/S0140-6736(13)61501-9 pmid: 23870813

Besozzi G, Ferrara A, Epifani E, Intini D, Apruzzese M, Provenzano A, et al. Acute stroke after intravitreal bevacizumab to treat choroidal neovascularization due to angioid streaks in pseudoxanthoma elasticum : a severe systemic adverse event after an off-label procedure. Int Ophthalmol. 2013;33(2):181-3. doi: 10.1007/s10792-012-9647-9 pmid: 23065017

IVAN Study Investigators; Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399-411. doi: 10.1016/j.ophtha.2012.04.015. Erratum in: Ophthalmology. 2012;119(8):1508. Erratum in: Ophthalmology. 2013;120(9):1719. pmid: 22578446

Micieli JA, Santiago P, Brent MH. Third nerve palsy following intravitreal anti-VEGF therapy for bilateral neovascular age-related macular degeneration. Acta Ophthalmol. 2011;89(1):e99-100. doi: 10.1111/j.1755-3768.2009.01778.x pmid: 19925526

CATT Research Group; Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-908. doi: 10.1056/NEJMoa1102673 pmid: 21526923

Luu ST, Gray T, Warrier SK, Patel I, Muecke JS, Casson R, et al. Retrospective study of an as required dosing regimen of intravitreal bevacizumab in neovascular age-related macular degeneration in an Australian population. Clin Exp Ophthalmol. 2010;38(7):659-63. doi: 10.1111/j.1442-9071.2010.02309.x pmid: 20456433

Yohendran J, Chauhan D. Erectile dysfunction following intravitreal bevacizumab. Middle East Afr J Ophthalmol. 2010;17(3):281-4. doi: 10.4103/0974-9233.65497 pmid: 20844689

Cakmak HB, Toklu Y, Yorgun MA, Sim?ek S. Isolated sixth nerve palsy after intravitreal bevacizumab injection. Strabismus. 2010;18(1):18-20. doi: 10.3109/09273970903567626 pmid: 20230202

Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, et al; ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ. 2010;340:c2459. doi: 10.1136/bmj.c2459 pmid: 20538634

Petrou P, Georgalas I, Giavaras G, Anastasiou E, Ntana Z, Petrou C. Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmol. 2010;88(4):e136. doi: 10.1111/j.1755-3768.2009.01572.x pmid: 19740128

Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol. 2010;128(10):1273-9. doi: 10.1001/archophthalmol.2010.223. Erratum in: Arch Ophthalmol. 2010;128(12):1623. pmid: 20937996

Potter MJ, Claudio CC, Szabo SM. A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study. Br J Ophthalmol. 2010;94(2):174-9. doi: 10.1136/bjo.2008.155531 pmid: 19520690

Byeon SH, Kwon OW, Lee SC. Transient global amnesia following intravitreal injection of bevacizumab. Acta Ophthalmol. 2009;87(5):570. doi: 10.1111/j.1755-3768.2008.01216.x pmid: 18537925

Kaiser PK; Registry of Visudyne AMD Therapy Writing Committee; Boyer DS, Garcia R, Hao Y, Hughes MS, Jabbour NM, Kaiser PK, et al. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2009;116(4):747-55, 755.e1. doi: 10.1016/j.ophtha.2008.12.057 pmid: 19243834

Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology. 2009;116(6):1142-50. doi: 10.1016/j.ophtha.2009.01.011 pmid: 19376585

Fong KC, Kirkpatrick N, Mohamed Q, Johnston RL. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment. Clin Exp Ophthalmol. 2008;36(8):748-55. doi: 10.1111/j.1442-9071.2008.01873.x pmid: 19128380

Wong LJ, Desai RU, Jain A, Feliciano D, Moshfeghi DM, Sanislo SR, et al. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Retina. 2008;28(8):1151-8. doi: 10.1097/IAE.0b013e31817e100f pmid: 18685542

Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, et al; Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246(1):81-7. doi: 10.1007/s00417-007-0660-z pmid: 17674014

Shima C, Sakaguchi H, Gomi F, Kamei M, Ikuno Y, Oshima Y, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol. 2008;86(4):372-6. doi: 10.1111/j.1600-0420.2007.01067.x pmid: 18028234

Diabetic Retinopathy Clinical Research Network; Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114(10):1860-7. doi: 10.1016/j.ophtha.2007.05.062 pmid: 17698196

Park HJ, Guy J. Sixth nerve palsy post intravitreal bevacizumab for AMD: a new possibly causal relationship and complication? Binocul Vis Strabismus Q. 2007;22(4):209. pmid: 18163895

Rodrigues EB, Shiroma H, Meyer CH, Maia M, Farah ME. Metrorrhagia after intravitreal injection of bevacizumab. Acta Ophthalmol Scand. 2007;85(8):915-6. doi: 10.1111/j.1600-0420.2007.00968.x pmid: 17645422

Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology. 2006;113(11):2002.e1-12. doi: 10.1016/j.ophtha.2006.05.070 pmid: 17027972

Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90(11):1344-9. doi: 10.1136/bjo.2006.099598 pmid: 16854824

Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26(4):383-90. doi: 10.1097/01.iae.0000238561.99283.0e pmid: 16603955

Pellé G, Shweke N, Duong Van Huyen JP, Tricot L, Hessaïne S, Frémeaux-Bacchi V, et al. Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors. Am J Kidney Dis. 2011;57(5):756-9. doi: 10.1053/j.ajkd.2010.11.030 pmid: 21295897

Saif MW, Longo WL, Israel G. Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer. Clin Colorectal Cancer. 2008;7(2):144-8. doi: 10.3816/CCC.2008.n.020 pmid: 18501075

Shye M, Hanna RM, Patel SS, Tram-Tran N, Hou J, Mccannel C, et al. Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy. Clin Kidney J. 2020;13(6):969-980. doi: 10.1093/ckj/sfaa049 pmid: 33391740

Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004;65(6):2003-17. doi: 10.1111/j.1523-1755.2004.00621.x pmid: 15149314

Bagheri S, Dormanesh B, Afarid M, Sagheb MM. Proteinuria and Renal Dysfunction after Intravitreal Injection of Bevacizumab in Patients with Diabetic Nephropathy: A Prospective Observational Study. Galen Med J. 2018;7:e1299. doi: 10.22086/gmj.v0i0.1299 pmid: 34466447

Borrego Utiel FJ, Luque Barona R, Pérez Del Barrio P, Borrego Hinojosa J, Ramírez Tortosa C. Acute Kidney Injury due to granulomatous interstitial nephritis induced by tramadol administration. Nefrologia (Engl Ed). 2018;38(2):227-228. English, Spanish. doi: 10.1016/j.nefro.2017.05.005 pmid: 29471961

Joss N, Morris S, Young B, Geddes C. Granulomatous interstitial nephritis. Clin J Am Soc Nephrol. 2007;2(2):222-30. doi: 10.2215/CJN.01790506 pmid: 17699417

Costagliola C, Agnifili L, Arcidiacono B, Duse S, Fasanella V, Mastropasqua R, et al. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration. Expert Opin Biol Ther. 2012;12(10):1299-313. doi: 10.1517/14712598.2012.707176 pmid: 22866908

Das A, McGuire PG, Rangasamy S. Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets. Ophthalmology. 2015;122(7):1375-94. doi: 10.1016/j.ophtha.2015.03.024 pmid: 25935789

Semeraro F, Morescalchi F, Duse S, Gambicorti E, Cancarini A, Costagliola C. Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection. Curr Drug Metab. 2015;16(7):572-84. doi: 10.2174/1389200216666151001120831 pmid: 26424177

Popescu V, Pricopie S, Totir M, Iancu R, Yasyn S, Alexandrescu C. Clinical use of Bevacizumab in treating refractory glaucoma. J Med Life. 2015;8(1):8-12. pmid: 25914729

Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab. Oncologist. 2010;15(8):819-25. doi: 10.1634/theoncologist.2009-0317 pmid: 20688807

  • Abstract Viewed: 0 times
  • Full Text PDF Downloaded: 0 times

Download Statastics

Open Journal Systems
Make a Submission